DL-dimyristoylphosphatidylcholine

DL-Dimyristoylphosphatidylcholine Overview

DL-dimyristoylphosphatidylcholine (commonly abbreviated as DMPC) is a synthetic zwitterionic phospholipid. Chemically, it belongs to the phosphatidylcholines class within the glycerophospholipids superclass. Structurally, it consists of a glycerol-3-phosphocholine backbone esterified to two saturated 14-carbon fatty acid chains (myristic acid).

In clinical pharmacology, nanomedicine, and drug delivery systems, DMPC is classified as a pharmaceutical excipient, liposomal constituent, and solubilizing agent (ATC categories for lipids, membrane lipids, and laboratory reagents). It is not an active therapeutic pharmaceutical ingredient and possesses no independent pharmacological disease indication. Instead, DMPC is utilized as a structural lipid carrier in commercial liposomal and lipid-complex drug formulations such as the intravenous antifungal lipid complex Abelcet (Amphotericin B Lipid Complex) as well as in lipid nanoparticle (LNP) delivery vehicles. It is also extensively used in biochemical research to model biological membranes and lipid bilayers.

What Is DL-Dimyristoylphosphatidylcholine and How Does It Work?

DMPC is a structural amphiphilic phospholipid that functions as a liposomal bilayer building block and solubilizing lipid complex constituent.

Its primary chemical, physiological, and formulation mechanisms include:

• Amphiphilic Self-Assembly: DMPC contains a hydrophilic polar head group (phosphocholine) and two hydrophobic non-polar fatty acid tails (myristoyl chains). In aqueous environments, it spontaneously self-assembles into closed spherical lipid bilayers (liposomes), lipid complexes, or mixed micelles.
• Drug Solubilization & Encapsulation: The hydrophobic core created by the saturated 14-carbon myristoyl chains traps hydrophobic or poorly soluble active drugs (such as Amphotericin B). The hydrophilic phosphocholine exterior faces outward, maintaining high solubility and dispersion within aqueous parenteral fluids and systemic blood.
• Reduction of Active Drug Toxicity: In lipid-complex formulations (such as Abelcet, which combines DMPC with dimyristoylphosphatidylglycerol [DMPG] and Amphotericin B), binding the active drug to the lipid matrix significantly alters systemic drug distribution. This lowers free drug exposure to vulnerable tissues (such as renal tubular membranes), markedly reducing nephrotoxicity while preserving antimicrobial efficacy.
• Membrane Interaction & Apolipoprotein Binding: Biophysical studies demonstrate that DMPC lipid complexes bind to Apolipoprotein A-I, participating in high-density lipoprotein (HDL) particle remodeling and lipid membrane interactions.

Is DL-Dimyristoylphosphatidylcholine FDA Approved?

Yes, DL-Dimyristoylphosphatidylcholine is approved by the US FDA as an inactive pharmaceutical ingredient. It received its initial FDA clearance as a liposomal structural lipid excipient on November 20, 1995 within the approved prescription product Abelcet (Amphotericin B Lipid Complex Injection, NDA 050724). While it holds active listing in the FDA Inactive Ingredient Database (IID) for intravenous formulations, it is not approved as a standalone active pharmaceutical drug because it possesses no intrinsic therapeutic activity.

What Is DL-Dimyristoylphosphatidylcholine Used For?

• Structural lipid constituent in parenteral liposomal and lipid-complex formulations to solubilize lipophilic active drugs (e.g., Amphotericin B Lipid Complex for severe invasive fungal infections).
• Excipient in lipid nanoparticle (LNP) systems for targeted drug delivery and gene therapy vectors.
• Biophysical laboratory research reagent for constructing artificial lipid bilayers, bicelles, and model biological membranes.

Before Using Formulations Containing DMPC: Contraindications & Precautions

Do not administer DMPC-containing preparations if there is a documented severe hypersensitivity to DMPC, synthetic phosphatidylcholines, or any active drug/excipient within the specific combination product (e.g., a severe allergy to Amphotericin B when using Abelcet). DMPC is an FDA-approved inactive pharmaceutical excipient and structural lipid carrier; it possesses no independent therapeutic activity.

Who Should Not Receive DMPC-Containing Formulations?

• Patients with a documented severe hypersensitivity to DMPC, synthetic phosphatidylcholines, or any active drug/excipient within the specific combination product (e.g., severe allergy to Amphotericin B when receiving Abelcet).
• Specific contraindications are dictated entirely by the active pharmaceutical ingredient co-formulated with DMPC.

DMPC, Pregnancy & Fertility

DMPC is a synthetic analog of naturally occurring cell membrane phospholipids. As an inactive excipient, it undergoes normal metabolic degradation by endogenous phospholipases into fatty acids and choline. Pregnancy considerations, teratogenicity risks, and lactation safety depend strictly on the active pharmaceutical agent co-administered with DMPC.

Tell Your Doctor Before Receiving DMPC Formulations

Inform your physician if you have a history of severe allergies to liposomal products, lipid emulsions, or specific active drugs.

DMPC Dosage & Administration

DMPC has no standalone therapeutic dosage. Clinical dosing is governed entirely by the co-formulated active pharmaceutical ingredient within the lipid matrix. For example, in Abelcet Injection (which contains 3.4 mg DMPC and 1.5 mg DMPG per 5 mg Amphotericin B per mL), the standard adult and pediatric dosage for invasive fungal infections is 5 mg/kg of body weight daily via intravenous infusion.

Standard Dosing Guidelines

• Dosing is determined entirely by the active pharmaceutical agent formulated within the lipid matrix. DMPC itself has no separate therapeutic dose.
• Example (Abelcet Injection): Formulated with 3.4 mg DMPC and 1.5 mg DMPG per 5 mg Amphotericin B per mL. Standard adult and pediatric dosage for invasive fungal infections is 5 mg/kg of body weight administered intravenously once daily.

How DMPC Formulations Are Administered

• Administered strictly via the route specified by the co-formulated active drug (most commonly intravenous infusion).
• Parenteral lipid complexes must be diluted in compatible infusion fluids (such as 5% Dextrose Injection) according to strict manufacturer protocols. Do not mix with saline solutions or other medications that induce lipid precipitation.

Clinical Efficacy & Research

Biophysical and nanomedical research confirms that DMPC is an ideal structural lipid for parenteral drug delivery systems. Its defined phase-transition temperature (approximately 23 degrees C) allows for stable liposome formation at room temperature and controlled fluidization at physiological body temperature (37 degrees C). Clinical trials of DMPC-containing lipid complexes demonstrate that incorporating toxic lipophilic drugs (like Amphotericin B) into a DMPC/DMPG lipid ribbon matrix reduces treatment-limiting side effects (such as acute renal failure) while maintaining therapeutic tissue concentrations.

Side Effects & Safety Profile

As a non-toxic, biodegradable lipid, DMPC does not directly cause systemic toxicity. Side effects associated with DMPC-containing products are driven by the active drug or acute physical infusion reactions to lipid particles. Common infusion-related reactions include fever, chills, rigors, nausea, vomiting, mild transient hypotension, or flushing.

Common Side Effects

Side effects observed during infusion of DMPC-containing formulations are primarily driven by the active drug or acute physical infusion reactions to lipid nanoparticles:

• Systemic infusion reactions: Fever, chills, rigors, nausea, and vomiting during IV administration.
• Mild transient hypotension or flushing.

Serious Adverse Events

• Severe anaphylactic or anaphylactoid reactions to lipid complexes.
• Acute infusion-related hypoxia, bronchospasm, or severe back pain (pseudo-allergy / CARPA reactions associated with liposomal IV infusions).

Managing Side Effects

Infusion-related reactions to lipid formulations can often be managed by slowing the IV infusion rate and pre-medicating with antihistamines, acetaminophen, or low-dose corticosteroids.

Drug Interactions & What to Avoid

DMPC possesses no direct receptor-mediated chemical drug interactions; all clinical drug-drug interactions are dictated by the co-formulated active drug. Parenteral lipid complexes containing DMPC are physically incompatible with electrolyte-rich solutions (such as 0.9% Normal Saline) and can precipitate or undergo phase separation if mixed in the same IV line.

Drug Interactions

• DMPC does not possess direct receptor-mediated chemical drug interactions.
• Co-formulated active drugs determine all clinical drug-drug interactions.
• Physical Incompatibility: Liposomal and lipid-complex preparations containing DMPC can precipitate or break phase if mixed in the same IV line with electrolyte-dense solutions (like normal saline) or incompatible co-infused drugs.

Food & Alcohol

Systemic food and alcohol interactions are governed by the specific active drug co-administered with DMPC.

Overdose, Emergency & Storage

Because DMPC is an inactive lipid carrier, overdose management pertains strictly to the co-formulated active pharmaceutical ingredient, requiring immediate discontinuation of the infusion and supportive clinical care.

Overdose Management

Because DMPC is a non-toxic lipid carrier, overdose concerns pertain strictly to the active pharmaceutical ingredient. Overdosage of lipid formulations requires supportive clinical care and immediate discontinuation of the infusion.

How to Store DMPC Formulations

Commercial drug products containing DMPC (like Abelcet) must be stored under refrigeration between 2 degrees C and 8 degrees C (36 degrees F to 46 degrees F). Do not freeze. Protect vials from light and excessive heat.

Patient Management & Monitoring

Laboratory and clinical monitoring protocols are dictated by the active drug (e.g., monitoring serum creatinine, BUN, electrolytes, and hepatic function during Abelcet therapy). Follow strict aseptic technique and specific dilution protocols during preparation.

Monitoring Protocols

• Laboratory and clinical monitoring are dictated by the active drug (e.g., monitoring serum creatinine, BUN, potassium, and liver function during lipid-complex antifungal therapy).

Key Clinical Do’s and Don’ts

• Do follow specific dilution and handling instructions for lipid-complex IV preparations.
• Do inspect lipid suspensions for phase separation or particulate matter prior to administration.
• Do not mix DMPC lipid infusions with saline or other drugs in the same IV line.

Frequently Asked Questions

References

• DrugBank Database – DL-Dimyristoylphosphatidylcholine Profile (DB11283)
• Classyfire Database – Phosphatidylcholines Chemical Taxonomy Profile

Legal Disclaimer

The detailed medical and chemical information provided on this specific web page is intended strictly for educational and informational purposes regarding complex pharmacological mechanisms. It absolutely does not constitute professional medical advice, medical diagnosis, or specific treatment recommendations. Always consult a licensed healthcare provider before making any personal decisions regarding complex medical conditions, medication adjustments, or dietary changes.